Lv41
568 积分 2022-06-14 加入
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
4小时前
待确认
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
4天前
已完结
BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study
7天前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
24天前
已完结
Use of Colony-Stimulating Factors in Patients With Systemic Lupus Erythematosus
1个月前
已完结
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review
1个月前
已完结
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus
1个月前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
2个月前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
2个月前
已完结
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases
2个月前
已完结
皖公网安备34019202002308
